Deepika Dhawan Selected Research

Deepika Dhawan Research Topics

Disease

21	Neoplasms (Cancer) 01/2023 - 12/2002
14	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 02/2006
12	Carcinoma (Carcinomatosis) 01/2022 - 01/2012
5	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2013
3	Transitional Cell Carcinoma 01/2014 - 05/2009
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 06/2023 - 06/2018
2	Lymphoma (Lymphomas) 06/2023 - 02/2014
2	Neutropenia 12/2018 - 01/2013
1	Autoimmune Diseases (Autoimmune Disease) 01/2023
1	Glioma (Gliomas) 01/2023
1	Papilloma (Papillomatosis) 11/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 10/2021
1	Krause-Kivlin syndrome 10/2021
1	Hypertension (High Blood Pressure) 10/2020
1	Noncommunicable Diseases 10/2020
1	Heart Diseases (Heart Disease) 10/2020
1	Abdominal Obesity 10/2020
1	Alcoholic Fatty Liver 10/2020
1	Kidney Diseases (Kidney Disease) 10/2020
1	Thrombocytopenia (Thrombopenia) 06/2018
1	Breast Neoplasms (Breast Cancer) 01/2015
1	Necrosis 12/2002
1	Melanoma (Melanoma, Malignant) 12/2002

Drug/Important Bio-Agent (IBA)

5	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2015
4	Complement System Proteins (Complement)IBA 11/2021 - 05/2009
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2009
3	Folic Acid (Vitamin M)FDA LinkGeneric 12/2018 - 01/2013
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2019
2	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2021
2	Peptides (Polypeptides)IBA 01/2022 - 01/2016
2	Cyclooxygenase InhibitorsIBA 01/2022 - 02/2006
2	Epidermal Growth Factor (EGF)IBA 01/2022 - 01/2020
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2010 - 04/2008
2	Celecoxib (Celebrex)FDA Link 05/2010 - 04/2008
1	Vincristine (Oncovin)FDA LinkGeneric 06/2023
1	thymidine kinase 1IBA 06/2023
1	Biomarkers (Surrogate Marker)IBA 06/2023
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2023
1	Prednisone (Sone)FDA LinkGeneric 06/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	Elastin-Like PolypeptidesIBA 01/2022
1	deracoxibIBA 01/2022
1	VemurafenibIBA 11/2021
1	EnzymesIBA 10/2021
1	AdipokinesIBA 10/2020
1	anthrax toxin (anthrax lethal factor)IBA 01/2020
1	MucinsIBA 01/2020
1	Immunotoxins (Immunotoxin)IBA 01/2020
1	Immune Checkpoint ProteinsIBA 01/2019
1	EC0531IBA 12/2018
1	LipidsIBA 07/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 07/2018
1	Messenger RNA (mRNA)IBA 06/2018
1	ClaudinsIBA 01/2018
1	ferric oxide (iron oxide)IBA 01/2016
1	glycol-chitosanIBA 01/2016
1	1,1'- (4,4,7,7- tetramethyl- 4,7- diazaundecamethylene)bis- 4- (3- methyl- 2,3- dihydro(benzo- 1,3- thiazole)- 2- methylidene)quinolinium (TOTO)IBA 01/2015
1	AntibodiesIBA 02/2014
1	EC0905IBA 01/2013
1	DNA (Deoxyribonucleic Acid)IBA 01/2012
1	Tumor Suppressor Protein p14ARF (p14ARF)IBA 01/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2010
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2008
1	Pentamidine (NebuPent)FDA LinkGeneric 12/2002
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 12/2002

Therapy/Procedure

15	Therapeutics 01/2023 - 12/2002
3	Drug Therapy (Chemotherapy) 06/2023 - 02/2014
3	Immunotherapy 01/2023 - 01/2017
1	Traction 01/2023
1	Cystectomy 05/2010